Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P23193
UPID:
TCEA1_HUMAN
Alternative names:
Transcription elongation factor S-II protein 1; Transcription elongation factor TFIIS.o
Alternative UPACC:
P23193; A6NF25; A8K339; Q15563; Q6FG87
Background:
Transcription elongation factor A protein 1, also known as Transcription elongation factor S-II protein 1 or TFIIS.o, plays a crucial role in RNA polymerase II transcription elongation. It is instrumental in overcoming template-encoded arresting sites that trap elongating RNA polymerases, thereby facilitating the resumption of transcription from a new 3'-terminus.
Therapeutic significance:
Understanding the role of Transcription elongation factor A protein 1 could open doors to potential therapeutic strategies.